Harbour BioMed Announces Multi-Year Transgenic Platform Licensing Agreement with Innovent Biologics, Inc. for Fully Human Monoclonal Antibody Drug Discovery
「Innovent joins more than 30 companies and academic institutions globally as licensees to our transgenic mouse platforms for antibody discovery,」 said Dr. Jingsong Wang, CEO of Harbour BioMed. 「The......